Akash Kulgod pointed out that analytical chemistry standards like GCMS detect volatile compounds at parts per million, whereas canine olfactory bulbs detect parts per trillion. This sensitivity difference allows dogs to spot stage 1 and 2 cancers easily while ignoring external confounds like recent smoking or specific diets.
Akash Kulgod shared how Dognosis partnered with Singapore security forces to deploy canine wearables after explosions. Rather than relying on a handler visually reading a dog, the harness pairs GPS tracking with real-time EEG readouts to automatically project chemical residue heatmaps across a full 3D spatial model.
Akash Kulgod observed that dogs naturally experience off-days roughly 10% of the time, degrading test consistency. Dognosis addresses this by having five dogs sniff each sample while AI models track neurological stress and engagement. The system dynamically downweights scores from unfocused dogs to produce a reliable consensus.
Akash Kulgod noted that artificial intelligence models can process visual and auditory data but cannot smell because no internet of smells exists. Dognosis plans to record dog neural representations of odors to build a perceptual smell dataset, creating reinforcement learning from canine feedback to finally teach AI olfaction.
Akash Kulgod explained that training dogs to give binary physical alerts like sitting or pawing takes 12 months and loses nuanced data. Replacing physical actions with brain-computer interfaces cut training down to eight weeks. Sensors capture brainwaves and heart rates to measure confidence, focus, and ambiguity directly.
Akash Kulgod noted that because baseline cancer prevalence in healthy populations is under 1%, even tests with 90% or 99% accuracy create massive false positives. Dognosis solves this statistical trap by using breath as an initial sensitive triage, followed by imaging to confirm true structural abnormalities.
Akash Kulgod shared that Dognosis gathered 10,000 patient samples in two years while remaining seed funded by operating in India. Taking advantage of strong local medical infrastructure and dollar-to-rupee cost arbitrage allowed the company to run massive, diverse clinical trials far cheaper and faster than in the United States.
